SYNTIS BIO INC
Oral peptide therapeutics using novel formulation and delivery technology
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2022
- Latest Form D
- $25M, Jul 2025
- Total capital
- $47.5M
- Federal grants
- $5M
- 8 awards · 2024–2026
- Rank in peer group#5 of 20
- Private capital raised
- $42.5M
- 3 Form D · last Jul 2025
- 16 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 14 pending · first 2024
- Rank in peer group#7 of 20
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Polymer Epithelial Lining for the Oral Delivery of Macromolecules$1.2M
- Federal grantHealth and Human S · Phase II · Development of an Oral Methionine-Gamma-Lyase Enzyme for the Treatment of Homocystinuria$347K
- Federal grantHealth and Human S · Phase II · Development of Once-daily Oral Treatment for Maple Syrup Urine Disease$344K
- Federal grantHealth and Human S · Phase II · Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism$325K
- Federal grantHealth and Human S · Phase II · Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery$916K
- Private capital raisedForm D · SEC · 3rd filing$25M
- Federal grantHealth and Human S · Phase II · Polymer Epithelial Lining for the Oral Delivery of Macromolecules$1.2M
- Private capital raisedForm D · SEC · 2nd filing$6.3M
- Private capital raisedForm D · SEC · 1st filing$11.2M
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery$323K
- Federal grantHealth and Human S · Phase II · Polymer Epithelial Lining for the Oral Delivery of Macromolecules$349K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 20 peers
Line = medianBiotech · Material
- Federal grants#5 · top 25%
- Granted patents#7 · top 35%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carlo Giovanni TraversoDirectorNamed in SEC Form D filings
- CARLO GIOVANNI TRAVERSODirectorNamed in SEC Form D filings
- Chenny ZhangDirectorNamed in SEC Form D filings
- Martin MadausDirectorNamed in SEC Form D filings
- Michael NannizziDirectorNamed in SEC Form D filings
- Rahul DhandaExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- ROBERT GIOVANNI LANGERDirectorNamed in SEC Form D filings
- Teymour Boutros-GhaliDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 17- GrantedEngineered Leucine DecarboxylasesUSPTOUS 12,502,421
- PendingForms And Compositions Of Sodium ChenodeoxycholateUSPTOApplication 18851936
- PendingEngineered Methionine Gamma Lyase VariantsUSPTOApplication 18826026
Show all 17 patent records
- Engineered Leucine DecarboxylasesDec 23, 2025 · US 12,502,421Granted
- Forms And Compositions Of Sodium ChenodeoxycholateJun 26, 2025 · Application 18851936Pending
- Engineered Methionine Gamma Lyase VariantsMar 27, 2025 · Application 18826026Pending
- Engineered Leucine DecarboxylasesMar 4, 2025 · US 12,241,100Granted
- Engineered Methionine Gamma Lyase VariantsOct 8, 2024 · US 12,110,521Granted
- Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsAug 8, 2024 · Application 18418090Pending
- Engineered Leucine DecarboxylasesJan 18, 2024 · Application 18363976Pending
- Forms And Compositions Of Sodium ChenodeoxycholateApplication PCTUS2023016486Pending
- Gastrointestinal Synthetic Epithelial Linings With Permeation EnhancersApplication 63480921Pending
- Engineered Leucine DecarboxylasesApplication PCTUS2022079089Pending
- Synergistic Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication 19517360Pending
- Synergistic Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication PCTUS2024049085Pending
- Synergistic Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication 63673614Pending
- Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication PCTUS2024012284Pending
- Synergistic Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication 63623109Pending
- Synergistic Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication 63541237Pending
- Permeation Enhancers For Gastrointestinal Synthetic Epithelial LiningsApplication 63541238Pending
Related companies, and why
- Lassogen, Inc.Similar federal contract value in Biotech · null in contracts
- ONC.AI, INC.Similar federal contract value in Biotech · null in contracts
- PROMAKHOS THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- BEAT BIOTHERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- PNA INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
- Arrevus, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .